LifeTech Capital

In a report published Monday, LifeTech Capital analyst Stephen M. Dunn reiterated a Neutral rating on Echo Therapeutics (NASDAQ: ECTE). In the report, LifeTech Capital noted, “Maintaining Neutral Rating: We continue to believe Echo's Symphony tCGM remains a world-class technology trapped under a...

In a report published Monday, LifeTech Capital analyst Stephen M. Dunn downgraded the rating on Echo Therapeutics (NASDAQ: ECTE) from Strong Speculative Buy to Neutral, and removed the $3.75 price target. In the report, LifeTech Capital noted, “Echo announced a $12M capital raise at $2.70 ($0....

In a report published Wednesday, LifeTech Capital analyst Stephen M. Dunn reiterated a Strong Speculative Buy rating on Echo Therapeutics (NASDAQ: ECTE), but lowered the price target from $5.00 to $3.75. In the report, Dunn noted, “Based on clinical progress for Echo's Symphony tCGM system, we are...

LifeTech Capital has published a research report on Navidea Biopharmaceuticals (NYSE: NAVB) after the company announced yesterday that the company has entered into a deal with Alseres Pharmaceuticals (formerly Boston Life Sciences). In the report, LifeTech writes, "After market close yesterday,...

In a published note, LifeTech Capital downgrades NovaBay Pharmaceuticals, Inc. (NYSE: NBY) to Neutral from Strong and drops its price target from $2.50 for $1.25 on trading liquidity risk. According to LifeTech, “Despite several potential catalysts in 2012 such as UCBE and Impetigo Phase II data (...

LifeTech Capital has downgraded NovaBay Pharmaceuticals (NYSE: NBY) to Neutral.

A report from LifeTech Capital reiterates its Strong Buy rating and $4.75 price target on Oculus Innovative Sciences (NASDAQ: OCLS). The report states, “Investors should note that top line sales and gross margins will experience seasonal fluctuations as the equine animal health business decreases...

LifeTech Capital maintained its Bionovo (NASDAQ: BNVI) Strong Speculative Buy rating and lowered its Bionovo price target from $7.50 to $5 in a research report published today. In the report, LifeTech Capital states, "Menerba could become the first botanical blockbuster drug which we believe...

LifeTech Capital reiterated its Buy rating on NovaBay (NYSE: NBY). At the same time, the rating agency left its price target on the company's stock unchanged at $2.50. On Friday, NovaBay closed the day at $1.02.

LifeTech Capital raised its StemCells (NASDAQ: STEM) (NASDAQ: STEMD) price target from $1.60 to $8 and maintained its Strong Speculative Buy rating in a research report published today. In the report, LifeTech Capital states, "StemCells Inc. executed a 1:10 reverse split on July 6th and will trade...

LifeTech Capital is out with its report today on Oculus Innovative Sciences (NASDAQ: OCLS), maintaining Strong Buy. In a note to clients, LifeTech Capital writes, "We believe shares of Oculus Innovative Sciences are undervalued and are maintaining Oculus with a Strong Buy rating and a 12-18 month...

LifeTech Capital maintained its Echo Therapeutics (OTC: ECTE) Strong Speculative Buy and $6 price target in a research report published today. In the report, LifeTech Capital states, "Echo Therapeutics Symphony™ transdermal continuous glucose monitor (tCGM) system is a unique needle-free, wireless...

LifeTech Capital provided color on Neoprobe (OTC: NEOP) in a research report published today. LifeTech Capital maintains its Neoprobe Strong Speculative Buy rating and $5.75 price target. In the report, LifeTech Capital states, "We believe the weakness in Neoprobe shares is the result of...

LifeTech Capital downgraded its Marina Biotech (NASDAQ: MRNA) rating from Strong Speculative Buy to Neutral and lowered its Marina Biotech price target from $2.50 to $0.30 in a research report published today. LifeTech Capital In the report, LifeTech Capital states, "Although Marina's announced...

LifeTech Capital updated its Echo Therapeutics (OTC: ECTE) rating and price target with a Strong Speculative Buy and $6 price target in a research report published today. In the report, LifeTech Capital states, "Echo Therapeutics has moved their Headquarters to Philadelphia and they have added a...